scorecardresearch
Add as a preferred source on Google
Tuesday, September 30, 2025
TopicCDSCO

Topic: CDSCO

Use nimesulide only after exhausting first-line options—expert panel under drug regulator CDSCO

Last year, an ICMR panel even considered recommending all-India ban on popular painkiller amid concerns it could cause liver damage, which could turn life-threatening in some cases.

As CDSCO lifts suspension on eye drops designed to replace reading glasses, makers eye June launch

Doctors caution that the drug should be used only under strong and regular supervision of an ophthalmologist.

No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door

Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved in select countries by means of local clinical trials waiver.

Antibiotics launched in India will soon need CDSCO nod as drug resistance emerges as silent killer

In 2019, bacterial antimicrobial resistance killed between 3 lakh and 10.4 lakh people in India, according to a Lancet report.

Why a govt-appointed panel has recommended a complete ban on popular painkiller nimesulide

First launched in Italy in 1985, Nimesulide is available in India under brand names like Nimuwin, Nimutab, Nimopen, Nisulid, Nimdase, Nodard Plus, Nicip, Nimcap, Nicip-P and Nimupain.

Govt says no plan to ban heartburn drug ranitidine, carcinogenic impurities within safe limits

In 2019, evidence showed that an impurity in drug degrades over time to form probable carcinogenic compound. Ranitidine is sold as heartburn medicine under names Rantac, Aciloc & Zinetac.

Drug regulator considers making central nod mandatory for all antibiotics in India, even existing ones

This new proposal, being considered by CDSCO, comes in response to concerns over antimicrobial resistance emerging as a massive public health challenge across the globe, including in India.

India has a substandard, fake drugs problem. Lack of recall law, scrutiny is making matters worse

Underlining need for more accountability, experts also stress that govt data does not include fixed dose combination drugs, which account for over 40% of drugs sold in India.

Eye drop’s claim to replace glasses cost it the launch & sale nod. The controversy & safety concerns

Regulatory approval to Entod Pharma for PresVu, meant to treat presbyopia, was revoked as the firm marketed it as a 'replacement for reading glasses' & due to possible health risks.

‘Unauthorised promotion’, risk of unsafe use: Why CDSCO revoked nod for eye drops to replace glasses

Drugs Controller General of India, who heads CDSCO, says Entod pharma failed to reply satisfactorily to queries raised. Entod to challenge suspension of approval.

On Camera

Bodoland poll loss a wake-up call for Assam BJP. Zubeen’s death puts CM Sarma in a tight spot

Assam CM can’t celebrate that the Congress drew a blank in the Bodoland Territorial Council polls in 2010 as well as 2015, and bagged only one in 2020.

Market regulator SEBI clears Adani Group of impropriety alleged by Hindenburg Research

SEBI probe concluded that purported loans and fund transfers were paid back in full and did not amount to deceptive market practices or unreported related party transactions.

Aerial warfare analyst Tom Cooper faults India’s military PR, says Pakistan does it better

In post on social media, Cooper narrated experience of MiG-21 researcher from Germany who wanted to attend aircraft’s farewell ceremony in India, and the roadblocks he faced. 

Something’s hidden in the Oval Office photo of Trump, Munir, Sharif. India must look closely

What Munir has achieved with Trump is a return to normal, ironing out the post-Abbottabad crease. The White House picture gives us insight into how Pakistan survives, occasionally thrives and thinks.